

AccuSet™ HIV-1 Early Infection Performance Panel

0800-0394

INTENDED USE

The AccuSet™ HIV-1 Early Infection Performance Panel 0800-0394 is intended for use by diagnostic manufacturers, researchers, and clinical laboratories to develop, evaluate, or troubleshoot HIV-1 test methods. Characterized samples and comprehensive data are provided for comparative analysis. For research use only. Not for use in diagnostic procedures.

PRODUCT DESCRIPTION

This product is a 25-member panel consisting of undiluted, naturally occurring plasma samples collected from individual donors with an early HIV-1 infection. Panel members represent varying Fiebig stages including Eclipse and stages I - V. Each sample represents a single collection event. No preservatives were added.

Material Number: 0800-0394, 1 vial per member
25 members, 1.0 mL per vial

STORAGE

Panel members should be stored frozen at -70°C or colder to preserve HIV-1 RNA. HIV-1 antigen and antibody will be preserved at -20°C or colder. LGC SeraCare recommends that the panel members be divided into smaller aliquots to avoid multiple freeze-thaw cycles, if appropriate. If turbidity or particulate matter is observed, the samples should be centrifuged in accordance with each test kit manufacturer's instructions for sample preparation.

INTERPRETATION OF RESULTS

The Data Sheet for AccuSet HIV-1 Early Infection Performance Panel 0800-0394 is available at www.seracare.com. The Data Sheet lists results for panel members generated using commercially-available screening, monitoring, and confirmatory test methods. Tests were performed at LGC SeraCare or at recognized reference laboratories (RL) by individuals who routinely use these procedures. Information regarding specific test methods is available on the data sheet. Data Sheets are updated when new data are available.

LIMITATIONS

AccuSet HIV-1 Early Infection Performance Panel 0800-0394 is offered for research use only. Not for use in diagnostic procedures. Data are provided for informational purposes. LGC SeraCare Life Sciences does not claim that others can duplicate test results exactly.

PRECAUTIONS

These materials have not been treated and should be considered biohazardous. Follow Universal Precautions¹. Some panel members were found positive by tests for HIV-1 RNA, HIV-1 antigen and HIV-1 antibody. The units that make up this panel were tested and found negative for HBsAg and anti-HCV. This does not ensure the absence of these or other human pathogens.

Do not pipette by mouth. Do not smoke, eat, or drink in areas where specimens are handled.

These materials should be disposed of in a manner that will inactivate pathogenic agents.

REFERENCES

1. Siegel JD, Rhinehart E, Jackson M, Chiarello L, and the Healthcare Infection Control Practices Advisory Committee, 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings.

For assistance, contact LGC SeraCare at 508.244.6400.

The package insert for this panel can be found at www.seracare.com.

A printed copy of the package insert or data sheet may be requested by email at CDx-Info@LGCGroup.com or by phone at 508.244.6400.